Find us on:

Ready to try LDN treatment? Find a local LDN doctor in our free directory

Multiple Sclerosis (MS) is the world’s most common autoimmune neurological disease, as over 2.5 million people globally have some form of MS. MS is a demyelinating disease, meaning that it damages myelin, which in turn impairs the brain’s ability to communicate with the rest of the body.

In 2008, a six-month pilot trial was conducted by the San Raffaele Scientific Institute in Italy to test LDN on 40 patients with primary progressive multiple sclerosis (PPMS). The primary goal was to see if LDN is a safe and tolerable treatment. The results of this trial showed that LDN is indeed safe and tolerable, and during the six-month period neurological disability progression was halted in all but one patient.

In 2010, the University of California San Francisco conducted another pilot trial. Sixty subjects with MS participated in the trial to assess LDN’s effects on mental health quality of life (QoL). The study results showed that LDN use was associated with a significant improvement in several mental health quality of life measures, including pain relief.

In 2015, the Jondi-Shapoor University of Medical Sciences performed a double-blind study to see how much LDN could improve quality of life for MS patients. In this trial, 96 MS patients were split into two groups. At the end of the 4-month trial, the authors concluded that LDN was a safe treatment, and proposed that a longer trial duration would be needed to show meaningful improvements in physical and mental health.

Various types of MS and their symptoms have been studied in both human and animal trials. These include relapsing-remitting multiple sclerosis (RRMS), primary-progressive multiple sclerosis (PPMS) and symptoms including pain, spasticity, fatigue, depression, clinically isolated syndrome, and quality of life (QoL).

Several animal trials have been conducted in order to try and identify the specific type of MS that is most likely to benefit from LDN. LDN shows signs of being a safe and promising candidate for treating MS, and is already being prescribed by hundreds of physicians worldwide for treating patients suffering from MS.